mortality of 0.5 per 100 patient-years for patients with AI. 12 The worsening of the clinical condition frequently occurs rapidly. 7 As an increase in cortisol secretion is an important adaptive mechanism during stress, AC usually occurs in case of a relative cortisol deficit during stressful events (eg, infectious disease). 6, 13 A quick and sufficient treatment by parenteral glucocorticoid (GC) administration is essential. 14 However, parenteral GC administration in case of an emergency is often delayed. A retrospective study comparing reported time intervals with time targets recommended by an European expert panel revealed a delay of GC administration by medical professionals in 46% of cases. Only 54% of the patients received GC parenterally within 30 minutes (with a range of 2-2400 minutes) after presentation of the emergency card to the medical professional. Experts considered 30 minutes as a time limit for "card-injection-time" in case of an AC within the same trial. 15 Further studies indicate an insufficient knowledge of physicians on AI. 16, 17 Only 9.6% of the interviewed physicians identified all situations requiring GC adjustment correctly. 16 An inadequate management by medical professionals, leading to an increased risk to die from AC, is assumed. Equipment of patients with an emergency card and set (GC ampoules) and education in dose adaption as well as self-injection of GC [18] [19] [20] is recommended by guidelines. 14 In our recent retrospective analysis of management of AC, patients had been asked about crisis events that were several years ago. 15 It is thus highly likely that patients could not exactly remember the circumstances. To validate and extend the data obtained, we performed a prospective study on emergency management.
| ME THODS

| Study design and patients
The trial was conducted as a multicentre, questionnairebased, prospective study and complies with the Declaration of 
| Questionnaire
Patients who were willing to participate received a short questionnaire collecting data on the management of AE by the patients (or relatives) themselves and the consulted medical professional. The following aspects were evaluated: symptoms, onset, causes of acute health deterioration, way of GC administration (oral, intramuscular, subcutaneous, rectal), amount of GC administered, hospitalization and duration of hospital stay, time interval between onset of symptoms and contact to a medical professional, time interval between arrival of a medical professional and parenteral GC administration by the medical professional, time interval between GC administration and improvement of symptoms after parenteral GC administration. Furthermore, the patients were asked to provide their personal assessment of the emergency management and to make suggestions for improvement. The patients were instructed to send the completed questionnaire back in case of an AE. All patients that did not report to the study centre within 6 months were additionally contacted by phone. Furthermore, the patients were contacted by phone in case of a missing or implausible statement in the questionnaire. 
| Statistical analysis
| RE SULTS
| Study cohort
A total of 150 patients with AI (n = 104 with primary AI, n = 41
with secondary AI and n = 5 with iatrogenic AI) from three specialized centres in Germany were included. Thirty-six male and 86) and median duration of AI was 12 years (0.3-47). About 71%
(n = 107) of the patients had already participated in the German wide standardized education programme for patients with AI.
| Adrenal emergencies
Fifty-nine AE leading to parenteral GC administration in 39 patients were observed during an observation period of 191 patient-years. In two further cases, an acute worsening of the general state of health that was only treated by orally administered HC was reported and excluded from further analyses due to the absence of parenteral GC administration. No patient died during the observation period.
Patient characteristics are displayed in Table 1 . The frequency of AE was 31/100 patient-years (36/100 patient-years in primary compared to 24/100 patient-years in secondary AI). Main causes were febrile (n = 26) and gastrointestinal (n = 22) infections followed by accident (n = 3), surgery (n = 2), mental stress, painful hip luxation and discontinued GC intake by order of a physician (respective n = 1). ten patients stated "others" (without further description) and 3 patients "unknown" cause. A total of 49 patients stated one cause and 10 patients two causes. The reported symptoms are shown in Table 2 . by self-injection (relatives), 11.9% by emergency physician and 6.8%
| Management of adrenal emergencies
by family physician.
In 43 cases of AE, GC was injected by a medical professional. Comparison of outpatient (n = 27) vs inpatient (n = 34) treatment by chi-squared test (*P < .05).
TA B L E 2 Symptoms of the 59 adrenal emergencies (multiple answers were possible; n = 165)
self-injection (P = .093). About 45% of the patients received the GC injection within 30 minutes after showing the emergency card; 55%
had to wait longer. In one AE, the GC injection was refused by the attending physician, the patient subsequently administered GC by self-injection. In 26 cases, an initial GC injection was performed by the patient themselves or their relatives, which was followed by a further GC injection by a medical professional in 10 cases. Twelve patients injected GC subcutaneously and 13 patients intramuscularly, one patient indicated no further details on the route of parenteral administration. Self-injection of GC was performed 77.5 minutes 
| Hospitalization
Twenty-five patients (42%) were treated as outpatients, 17 patients (29%) were treated at a general ward and 17 (29%) patients at an intensive care unit. About 78% of the patients that did not adapt their oral GC dose (n = 9) had to be treated at a general ward or intensive care unit, compared to only 54% of the patients who initially increased their daily oral GC dose (n = 50) (P = .278).
After self-injection (by patients or relatives), 62% of the patients were treated on an outpatient basis, compared to only 27% after sole injection by a medical professional (P = .008); Figure 3B . Even after exclusion of patients that did not search professional medical help (n = 4), significantly (P = .041) more patients were treated on an outpatient basis after self-injection (55%) compared to sole injection by a medical professional (27%). The frequency of intensive care unit treatment was 19% after self-injection and 36% if injection was only performed by a medical professional, which, however, did not statistically differ (P = .149). The duration of hospitalization was not different after initial self-injection compared to the patients that did not self-inject (self-injection vs no self-injection; 2.1 days (Table 2) . Moreover, the number of symptoms was slightly, but not significantly, higher in patients that were treated on an inpatient basis (out-vs inpatient: 2 F I G U R E 3 Self-injection (by patients or relatives) vs injection by medical professional (emergency, clinic or family doctor). A, Time from the beginning of symptoms to glucocorticoid injection-self-injection (n = 26) vs sole injection by medical professional (MP) (n = 33); Analyses were performed by Mann-Whitney U test; ***P < .001. B, Hospitalization (outpatient, general ward, intensive care unit)-self-injection (n = 26) vs sole injection by medical professional (MP) (n = 33 patients, who received GC only by MP)
[1-6] vs 3 [1] [2] [3] [4] [5] [6] [7] ; P = .055). An additional comparison between outand inpatient treatment is displayed in Table 3 .
| Patient's evaluation of the emergency management
Only 17% of the patients felt that the management of the AE pro- 
| D ISCUSS I ON
The current study for the first time assessed emergency management within AI in a prospective setting showing large variability in emergency management. The median time from showing the emergency card to a medical professional to parenteral GC administration by a medical professional (card-injection-time) was 60 minutes (5-360) and only 45% of the patients received GC by a physician within 30 minutes, a time interval recently recommended by experts in the field. 15 This time interval is even longer compared to our previous retrospective analysis documenting a median card-injectiontime of 30 minutes (2-2400) with 54% of the patients receiving GCs within 30 minutes. 15 However, the range of time intervals was much larger than in the current study. This may in part be due to the retrospective nature of the analysis potentially leading to wrong time estimates. As 95% of the patients in the current study had already participated in a standardized education programme encouraging patients and their relatives to insist on parenteral GC injection in case of an AE, the lower variability might be explained by a higher number of patients insisting on timely GC administration. 20 Of note, card-injection-time (by medical professionals) was even shorter in those patients who had already performed self-injection in the course of the same emergency event.
Another interesting finding of our study is the number of patients that performed a self-injection (n = 26 AE) which lead to an Approximately 50% of the patients that performed a selfinjection administered HC subcutaneously. As this off-label way of HC injection was only evaluated in one small investigator initiated trial, 18 it is of interest that no differences regarding the injectionimprovement-time, after intramuscular and subcutaneous administration, were observed. These findings support the assumption of similar efficacy of intramuscular and subcutaneous injection of HC at least in the early stages of an AE. About 32.2% of patients performed a self-injection and 15.3% of patients received GCs parenterally by relatives. Although the number of patients that performed a self-injection was quite considerable, in the majority of cases, no self-injection was performed, despite 95%
TA B L E 3 Comparison of in-and outpatient treatment
of the patients participated in the German wide standardized education programme for patients with AI and were educated in preparation of the GC syringe and performance of self-injection. So far no "ready-to-use" pen or syringe is available. About 94% of the patients who did not self-inject indicated impaired general health condition that made it impossible to prepare and perform the GC self-injection as main reason and 52% of the patients reported that the inhibition threshold to inject themselves had been too high despite education. This clearly emphasizes the importance of simplification of self-injection.
Within this study, only 17% of the patients were of the opinion that the management of the AE was optimal. Previous studies demonstrated that GC administration is sometimes delayed by the attending physicians, 6, 12, 15 which might be ascribed to a lack of experience with a rather rare disease. Kampmeyer et al revealed that only a small number of interviewed physicians (9.6%) identified all situations requiring GC adjustment correctly. Interestingly, in our study, 66% of the patients believed that the emergency management by medical professionals does not need further improvement. However, 84% of the patients regarded simplification of self-injection as most important providing the possibility to manage the early phase of an emergency situation more independently.
Besides parenteral GC administration, our data indicate that an early oral dose adjustment seems to be helpful, too. At least 15% of the participating patients that suffered from an AE did not increase their oral GC dose. About 78% of these patients had to be treated at a general ward or intensive care unit, compared to only 54% of the patients who initially adapted their oral GC dose. Thus, in case of incipient AE, single oral GC dose increase may not be sufficient for treatment of the emergency but at least improves the course of such events. Consequently, patients should repeatedly be educated in dose adjustment including both oral intake and self-injection of GCs.
A more severe impairment of the general health status or at least special symptoms could have affected the hospitalization of patients, for example patients that were treated as inpatients had more often gastrointestinal symptoms ( Table 2) . As gastrointestinal symptoms are associated with a worse absorption of orally ingested HC and have frequently been described as symptoms or causes of AC, 6, 7, 9, 11, 12, 21 medical professionals might have been more cautious in these cases and preferred an inpatient treatment. However, the number of initial symptoms reported by the patients was not significantly different between patients who were treated as outpatients compared to those treated as inpatients (2 [1-6] vs 3 [1] [2] [3] [4] [5] [6] [7] ; P = .055).
The causes and symptoms of the AE that were documented during this trial assort mostly with the observations from previous studies. 7, 9, 11, 12, 22 The high frequency of AE (31/100 patient-years) that was observed within this study is certainly overestimated, as all recruiting study centres predominantly included patients with an alleged high risk to develop an AC (eg, patients that already experienced one or even multiple AC in the past or patients with primary AI). Accordingly, the number of included patients with primary AI is higher compared to patients with secondary AI. In general, the definition of AC is difficult. In our study, we focused on emergency situations where parenteral glucocorticoid administration becomes necessary.
Although a considerable number of AE has been evaluated within this prospective study, our study has several Oldenburg for the excellent co-operation. Furthermore, the authors thank all participating patients.
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